<DOC>
	<DOC>NCT01900249</DOC>
	<brief_summary>The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.</brief_summary>
	<brief_title>To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>A history of dry eye (based on the date of initial dry eye symptoms) Use of overthecounter (OTC) and/or prescription eye drops for dry eye symptoms Corneal fluorescein staining score of at least 2 in the inferior region History of, or a concurrent clinically significant illness, medical condition (other than Keratoconjunctivitis Sicca or Sj√∂gren's syndrome), or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study. Use of ophthalmic cyclosporine within 45 days of Visit 1. Use of any topical ophthalmic steroid within 2 weeks of Visit 1. Have worn contact lenses or anticipate using contact lenses during the study. Have a condition or be in a situation that the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. Have a history of alcohol or substance abuse that, in the judgment of the Investigator, may impair or risk the subject's full participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>